Atossa Therapeutics Files 8-K: Director Changes & Officer Compensation Updates
Ticker: ATOS · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.18, $439,700 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, director-changes
TL;DR
Atossa's 8-K shows director changes and officer comp updates, filed June 27.
AI Summary
On June 27, 2024, Atossa Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new directors, and updates to compensatory arrangements for certain officers. The company also reported on amendments to its articles of incorporation or bylaws and the submission of matters to a vote of security holders.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and officer roles, along with potential amendments to corporate governance, can introduce uncertainty and affect strategic direction.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 26-4753208 (identifier) — IRS Employer Identification No.
FAQ
Who departed as a director of Atossa Therapeutics, Inc.?
The filing indicates the departure of a director, but the specific name is not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2024.
What are the main categories of information covered in this 8-K filing?
The filing covers the departure of directors, election of directors, appointment of officers, compensatory arrangements, amendments to articles of incorporation/bylaws, and submission of matters to a vote of security holders.
In which state is Atossa Therapeutics, Inc. incorporated?
Atossa Therapeutics, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Atossa Therapeutics, Inc.?
The IRS Employer Identification Number for Atossa Therapeutics, Inc. is 26-4753208.
Filing Stats: 1,168 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-07-02 16:20:09
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
- $439,700 — n increase to her annual base salary to $439,700 and an increase to her target annual ca
Filing Documents
- atos-20240627.htm (8-K) — 92KB
- atos-ex3_1.htm (EX-3.1) — 11KB
- atos-ex10_1.htm (EX-10.1) — 152KB
- 0000950170-24-080497.txt ( ) — 426KB
- atos-20240627.xsd (EX-101.SCH) — 44KB
- atos-20240627_htm.xml (XML) — 6KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the Annual Meeting, the Company's stockholders also approved an amendment of the Company's Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") to increase the number of authorized shares of Common Stock from 175,000,000 to 350,000,000, which also has the effect of increasing the total number of authorized shares from 185,000,000 to 360,000,000 (the "Amendment"). On June 28, 2024, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing. The foregoing description of the Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below. (i) Election of Two Class III Directors The stockholders elected the two Class III directors by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Shu-Chih Chen, Ph.D. 28,619,224 3,778,904 27,879,201 H. Lawrence Remmel, Esq. 28,453,128 3,864,924 27,959,277 (ii) Ratification of Independent Auditor The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 58,330,064 1,449,110 498,155 0 (iii) Approval of an Amendment and Restatement of the 2020 Plan The stockholders approved an amendment and restatement of the 2020 Plan by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 20,792,908 10,620,891 904,253 27,959,277 (iv) Approval of an Amendment of the Certificate of Incorporation The stockholders approved an amendment of the Certificate of Incorporation by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 44,552,602 15,094,316 630,411 0 (v) Advisory Vote on Executive Compensation The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 23,453,687 7,079,748 1,784,257 27,959,637
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc. 10.1 Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as Amended 104 Cover page Interactive Data File (embedded within the Inline XBRL document) * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: July 2, 2024 By: /s/ Heather Rees Heather Rees Senior Vice President, Finance & Accounting